{"groups":[{"description":"Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)\n\nTadalafil: Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days\n\nLenalidomide: Lenalidomide will be administered as it was prior to study entry.\n\nDexamethasone: Dexamethasone will be administered as it was prior to study entry.\n\nClarithromycin: Clarithromycin will be administered as it was prior to study entry.","id":"FG000","title":"Tadalafil"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Lack of Efficacy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"One participant was a screen failure."}